NEOG Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of 33.55%. Neogen Corp.'s return on equity of -25.93% beat Amgen, Inc.'s return on equity of 95.55%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 26.13%. On the other hand Amgen, Inc. has an analysts' consensus of $331.59 which suggests that it could grow by 0.36%. Given that Neogen Corp. has higher upside potential than Amgen, Inc., analysts believe Neogen Corp. is more attractive than Amgen, Inc..

Neogen Corp. has a beta of 1.956, which suggesting that the stock is 95.564% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.551%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Neogen Corp. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Neogen Corp.'s net income of -$15.9M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Amgen, Inc.'s PE ratio is 25.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.28x versus 4.99x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myriad Genetics, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -13.32%. Neogen Corp.'s return on equity of -25.93% beat Myriad Genetics, Inc.'s return on equity of -69.09%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 26.13%. On the other hand Myriad Genetics, Inc. has an analysts' consensus of $8.24 which suggests that it could grow by 39.26%. Given that Myriad Genetics, Inc. has higher upside potential than Neogen Corp., analysts believe Myriad Genetics, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.956, which suggesting that the stock is 95.564% more volatile than S&P 500. In comparison Myriad Genetics, Inc. has a beta of 1.811, suggesting its more volatile than the S&P 500 by 81.11%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myriad Genetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Myriad Genetics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $224.7M, which are larger than Myriad Genetics, Inc. quarterly revenues of $205.7M. Neogen Corp.'s net income of -$15.9M is higher than Myriad Genetics, Inc.'s net income of -$27.4M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Myriad Genetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.28x versus 0.66x for Myriad Genetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -1338.77%. Neogen Corp.'s return on equity of -25.93% beat Outlook Therapeutics, Inc.'s return on equity of --.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 26.13%. On the other hand Outlook Therapeutics, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 1151.07%. Given that Outlook Therapeutics, Inc. has higher upside potential than Neogen Corp., analysts believe Outlook Therapeutics, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.956, which suggesting that the stock is 95.564% more volatile than S&P 500. In comparison Outlook Therapeutics, Inc. has a beta of 0.174, suggesting its less volatile than the S&P 500 by 82.557%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Outlook Therapeutics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $224.7M, which are larger than Outlook Therapeutics, Inc. quarterly revenues of $1.5M. Neogen Corp.'s net income of -$15.9M is higher than Outlook Therapeutics, Inc.'s net income of -$20.2M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Outlook Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.28x versus 10.52x for Outlook Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -44.78%. Neogen Corp.'s return on equity of -25.93% beat Teleflex, Inc.'s return on equity of -7.84%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 26.13%. On the other hand Teleflex, Inc. has an analysts' consensus of $131.29 which suggests that it could grow by 27.46%. Given that Teleflex, Inc. has higher upside potential than Neogen Corp., analysts believe Teleflex, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.956, which suggesting that the stock is 95.564% more volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.113%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.32% to investors and pays a quarterly dividend of $0.34 per share. Neogen Corp. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Neogen Corp.'s net income of -$15.9M is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.28x versus 1.46x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.